(Z)-3-aminoperacrylic acid

The peracid of (Z)-3-aminoacrylic acid where the acidic -OH group has been replaced by an -OOH group.


phenylalkylamine

An arylalkylamine in which the aryl group is phenyl.


OCTADECYLAMINE

An 18-carbon primary aliphatic amine.


DOI

An organoiodine compound that is amphetamine bearing two methoxy substituents at positions 2 and 5 as well as an iodo substituent at position 4.


An alkylamine that is pent-3-en-1-amine substituted by a methyl group ay position 4.


FM 1-43(2+)

A pyridinium cation with a 3-(triethylammonio)propyl substituent at the 1-position and a 4-(dibutylamino)styryl substituent at the 4-position.


R(-)amphetamine

A 1-phenylpropan-2-amine that has R configuration.


amantadine

A member of the class of  adamantanes that is used as an antiviral and  antiparkinson drug.


name: Ethanesulfonic acid, 2-(cyclohexylamino)-, monosodium salt


alpha-amino fatty acid

A fatty acid with an amino substituent at position C-2.


A primary aliphatic amine that is propan-1,2-diamine substituted by an isopropyl group at N(1) and a methyl group at position 2. Metabolite observed in cancer metabolism.


yanuthone M

A class I yanuthone that is yanuthone K in which the double bond at the terminal end of the farnesyl substituent has undergone hydration to afford the corresponding tertiary alcohol. Isolated from the filamentous fungus Aspergillus niger, it shows antifungal activity towards the pathogenic yeast Candida albicans (IC50 = 77.5 +-3.7 muM).


(Z)-dehydrotyrosine

A 2,3-dehydroamino acid resulting from the formal elimination of a molecule of hydrogen from the side-chain of tyrosine.


Disperse Blue 124

A monoazo compound consisting of diazene with a 5-nitrothiazol-2-yl group attached to one nitrogen and a substituted 4-aminophenyl group attached to the other; used as a dye standard for the assay of allergy-releasing dyes in textiles.


name: 5-[(4-methyl-1-piperidinyl)methyl]-1-[4-(1-pyrrolyl)-1,2,5-oxadiazol-3-yl]-4-triazolecarboxylic acid ethyl ester


omega-amino fatty acid

Any fatty acid n atoms long having an amino substituent at position n (omega).


(S)-fenpropidin

A 1-[3-(4-tert-butylphenyl)-2-methylpropyl]piperidine that has S configuration.


The N-(3-aminopropyl) derivative of 4-aminobutanal.


BUTYLAMINE

A primary aliphatic amine that is butane substituted by an amino group at position 1.


FENPROPIDIN

A racemate comprising equimolar amounts of (R)- and (S)-fenpropidin. A systemic fungicide, it is used for the control of foliar diseases in cereals and sugar beet.


dextropropoxyphene

The (1S,2R)-(+)-diastereoisomer of propoxyphene.


arylmethylamine

An aralkylamine consisting of methylamine in which one of the methyl hydrogens is replaced by any aromatic group.


A nitrile that is acrylonitrile in which the hydrogen attached to the same carbon as the cyano group has been replaced by an o-(trifluoromethyl)phenyl group, while the remaining hydrogens of the ethenyl group have been replaced by amino and (4-aminophenyl)sulfanyl groups. The configuration of the double bond is not specified. It is an inhibitor of MEK1 and MEK2.


An aryl sulfide that is (2Z,3Z)-bis[amino(sulfanyl)methylidene]butanedinitrile in which the sulfanyl hydrogens are replaced by 2-aminophenyl groups. An inhibitor of mitogen-activated protein kinase that also exhibits anti-cancer properties.


A primary aliphatic amine that is butan-2-amine substituted by a methyl group at position 2. Metabolite observed in cancer metabolism.


almotriptan

An indole compound having a 2-(dimethylamino)ethyl group at the 3-position and a (pyrrolidin-1-ylsulfonyl)methyl group at the 5-position.


butenafine

Trimethylamine in which hydrogen atoms attached to different methyl groups are substituted by 1-naphthyl and 4-tert-butylphenyl groups. It is an inhibitor of squalene epoxidase, an enzyme responsible for the creation of sterols needed in fungal cell membranes, and is used as its hydrochloride salt for treatment of dermatological fungal infections.


methyldopate

The ethyl ester of alpha-methyl-L-dopa.


lamotrigine

A member of the class of 1,2,4-triazines in which the triazene skeleton is substituted by amino groups at positions 3 and 5, and by a 2,3-dichlorophenyl group at position 6.


An amino dicarboxylic acid that is 4-aminohepta-2,4-dienoic acid which is substituted at position 6 by an oxo group [the (2Z,4E) isomer].


triethylamine

A tertiary amine that is ammonia in which each hydrogen atom is substituted by an ethyl group.


PicoGreen

A cyanine dye that is 1-phenylquinoline which is substituted at position 2 by a bis[3-(dimethylamino)propyl]amino group and at position 4 by a (3-methyl-1,3-benzothiazol-3-ium-2-yl)methylene group. The counter ion is not stated. A fluorochrome that selectively binds double-stranded DNA and has characteristics similar to that of SYBR-Green I.


cyproheptadine

The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.


amphetamines

Amines that constitute a class of central nervous system stimulants based on the structure of the parent amphetamine 1-phenylpropan-2-amine.


DIMETHYLADENINE

A tertiary amine that is adenine substituted at N-6 by geminal methyl groups.


A  primary arylamine that is aniline in which the hydrogens at the 2- and 4-positions are replaced by methyl groups. A clear to yellow liquid, it is used in production of certain dyes, pesticides and other chemicals.


A primary arylamine that is aniline in which the hydrogens at the 2- and 6-positions are replaced by methyl groups. It is used in the production of some anasthetics and other chemicals. It is a drug metabolite of lidocaine (local anasthetic).


name: N-[[4-(diethylamino)phenyl]methylideneamino]carbamic acid tert-butyl ester


LDS 751(1+)

A cationic C3 cyanine-type compound with 4-(dimethylamino)phenyl and 6-(dimethylamino)-1-ethylquinolinium-2-yl groups at either end.


8-aminooctanoic acid

An omega-amino fatty acid that is octanoic acid which carries an amino group at position 8.


A member of the class of bipyridines that is 2,2'-bipyridine in which the hydrogens situated para to the ring nitrogens have been replaced by methyl and 3-amino-2-methylbut-2-en-1-imino groups.


A phenylalkylamine that is benzene in which one of the hydrogens is substituted by a 4-aminobutyl group.


diphenylpyraline

A member of the class of  piperidines that is the benzhydryl ether derivative of 1-methyl-4-hydroxypiperidine. A sedating antihistamine, it is used as the hydrochloride for the symptomatic relief of allergic conditions including rhinitis and hay fever, and in pruritic skin disorders. It is also used as the teoclate salt (piprinhydrinate) as an ingredient in compound preparations for the symptomatic relief of coughs and the common cold.


ALISIAQUINONE C

An organic heterohexacyclic compound that is isolated from New Caledonian deep water sponge and exhibits antiplasmodial properties.


12-AMINODODECANOIC ACID

An omega-amino fatty acid that is dodecanoic acid in which one of the terminal amino hydrogens has been replaced by an amino group.


2-aminooctanoic acid

An alpha-amino fatty acid that is caprylic acid which is substituted at position 2 by an amino group.


A phenylalanine derivative that is phenylalanine in which the amino group is substituted by a [(E)-{[(Z)-2-amino-1,2-dicyanoethenyl]imino}methyl]amino group. It is a chemical intermediate for nucleotide synthesis.


ISOPROPYLAMINE

A member of the class of  alkylamines that is propane carrying an amino group at position 2.


vandetanib

A quinazoline that is 7-[(1-methylpiperidin-4-yl)methoxy]quinazoline bearing additional methoxy and 4-bromo-2-fluorophenylamino substituents at positions 6 and 4 respectively. Used for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.


A primary arylamine that is aniline in which the hydrogens at the 2- and 5-positions are replaced by methyl groups. It is used in the manufacture of dyes and other chemicals.


diaziquone

A 1,4-benzoquinone that is substituted at positions 2 and 5 have been replaced by aziridin-1-yl groups and at positions 3 and 6 by (ethoxycarbonyl)amino groups.


chloridazone-desphenyl

A heteroaryl hydroxy compound that is pyridazin-3-ol substituted by an amino group at position 5 and a chloro group at position 4. It is a metabolite of the herbicide chloridazone.


A secondary aliphatic amine that is sec-butylamine substituted by a methyl group at the N atom. Metabolite observed in cancer metabolism.


A primary aliphatic amine that is 3-aminopropan-1-ol in which the hydroxy group is replaced by a (2-ethylhexyl)oxy group.


A tertiary amine consisting of 1,2,3,4-tetrahydroquinoline having an N-methyl substituent.


diphenoxylate

A piperidinecarboxylate ester that is the ethyl ester of difenoxin.


sec-butylamine

A primary aliphatic amine that is butane in which one hydrogen at position 2 is replaced by an amino group. A fumigant fungicide with a high potential for bioaccumulation, it is not approved for fungicidal use in the European Union.


2-aminoacrylic acid

A 2,3-dehydroamino acid that is alanine which has been dehydrogenated to introduce a double bond between positions 2 and 3.


CERATAMINE A

An organic heterobicyclic compound, which is imidazo[4,5-d]azepin-5(6H)-one substituted by a 3,5-dibromo-4-methoxybenzyl group at position 4, a methyl group at position 6 and a methylamino group at position 2. It is an antimitotic alkaloid isolated from the marine sponge Pseudoceratina.


amezinium metilsulfate

A pyridazinium ion that is pyridazin-1-ium which is substituted by a phenyl, amino and methoxy groups at positions 1, 4 and 6, respectively.


methamphetamine

A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.


A monomethoxybenzene that is dopamine in which the hydroxy group at position 4 is replaced by a methoxy group.


cyclohexylamine

A primary aliphatic amine consisting of cyclohexane carrying an amino substituent.


ETHYLAMINE

A two-carbon primary aliphatic amine.


sevadicin

A non-ribosomal tripeptide with antibacterial activity of sequence D-Phe-D-Ala-Trp synthesized by the bee pathogenic bacterium Paenibacillus larvae.


primary amine

A compound formally derived from ammonia by replacing one hydrogen atom by a hydrocarbyl group.


A derivative of aniline in which the hydrogen at position 2 has been substituted by fluorine. It is used as a pharmaceutical intermediate


LOBELINE

An optically active piperidine alkaloid having a 2-oxo-2-phenylethyl substituent at the 2-position and a 2-hydroxy-2-phenylethyl group at the 6-position.


alkylamines

Any amine formally derived from ammonia by replacing one, two or three hydrogen atoms by alkyl groups.


A dinitrile that is succinonitrile in which the methylene hydrogens at positions 2 and 3 are substituted by amino(phenylsulfanyl)methylidene groups. It acts as an inhibitor of MEK (mitogen activated protein kinase kinase).


eschscholtzidine

A heteropentacyclic isoquinoline alkaloid having a tertiary amino bridging group.


deanol

A  tertiary amine that is ethanolamine having two N-methyl substituents.


name: N-[1-[4-(4-bromophenyl)-2-thiazolyl]-4-piperidinyl]carbamic acid tert-butyl ester


A member of the class of chromenes that is 7,7-dimethyl-5-oxo-5,6,7,8-tetrahydrochromene carrying additional amino, cyano and 3-cyclohexen-1-yl substituents at positions 2, 3 and 4 respectively.


dehydrosecodine

A member of the class of indoles that is methyl 2-(1H-indol-2-yl)prop-2-enoate in which the indole moiety has been substituted at position 3 by a 2-(5-ethylpyridin-1(2H)-yl)ethyl group. An intermediate in the biosynthesis of aspidosperma and iboga alkaloids.


ravidomycin

A C-glycosylated naphthoisochromene derivative obtained from Streptomyces ravidus; exhibits antibiotic and anticancer properties.


L-phenylalaninol

An amino alcohol resulting from the formal reduction of the carboxy group of L-phenylalanine to the corresponding alcohol.


(7R,8S)-7,8-diaminononanoic acid

The isomer of 7,8-diaminononanoic acid having (R)- and (S)- configurations at C-7 and C-8, respectively; an intermediate in the biosynthetic pathway of biotin. As biotin is made exclusively in plants and microorganisms, both the chemical structure and biosynthetic enzymes of DAPA are targets for the development of herbicides and antimicrobial drugs.


The (R)-enantiomer of 1-phenylethanamine.


tertiary amine

A compound formally derived from ammonia by replacing three hydrogen atoms by hydrocarbyl groups.


name: gallate catabolic process via gallate dioxygenase activity

category: biolink:BiologicalProcess biolink:Occurrent biolink:OntologyClass biolink:BiologicalProcessOrActivity biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing biolink:PhysicalEssenceOrOccurrent

description: The chemical reactions and pathways resulting in the breakdown of gallate, the anion of gallic acid, where the first step is the conversion of gallate to (1E)-4-oxobut-1-ene-1,2,4-tricarboxylate catalyzed by gallate dioxygenase.


aerobic gallate catabolic process

description: The chemical reactions and pathways resulting in the breakdown of gallate, the anion of gallic acid, in the presence of oxygen.


name: gallate catabolic process via 2-pyrone-4,6-dicarboxylate

description: The chemical reactions and pathways resulting in the breakdown of gallate, the anion of gallic acid, via the intermediate 2-pyrone-4,6-dicarboxylate.


zygodactyly type 2

category: biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing


non-syndromic syndactyly

description: A congenital condition characterized by webbing between the fingers and/or toes, joining the digits together. In rare cases, the joining of the fingers or toes may involve bony fusion between the digits. Common causes include Down Syndrome and hereditary syndactyly.


syndactyly type 5

description: Syndactyly type 5 (SD5) is a very rare congenital limb malformation characterized by postaxial syndactyly of hands and feet, associated with metacarpal and metatarsal fusion of fourth and fifth digits.


non-syndromic synpolydactyly

description: A synpolydactyly that is not part of a larger syndrome.


polysyndactyly 4

description: Polysyndactyly or PPD4 is a form of preaxial polydactyly of fingers, a limb malformation syndrome, characterized by the presence of a thumb showing the mildest degree of duplication, being broad, bifid or with radially deviated distal phalanx. Syndactyly of various degrees of third-and-fourth fingers is occasionally present.


syndactyly type 1

description: Syndactyly type 1 (SD1), also named zygodactyly in the past, is a distal limb malformation characterized by complete or partial webbing between the 3th and 4th fingers and/or the 2nd and 3rd toes.


name: mesoaxial synostotic syndactyly with phalangeal reduction

description: Mesoaxial synostotic syndactyly (MSSD) with phalangeal reduction is a novel and distinct form of non-syndromic syndactyly including complete syndactyly of the 3rd and 4th fingers with synostoses of the corresponding metacarpals and associated single phalanges, syndactyly of the 2nd and 3rd toes and 5th finger clinodactyly.


syndactyly type 6

description: Syndactyly type 6 is a rare, genetic, non-syndromic, congenital limb malformation characterized by unilateral fusion of second to fifth fingers, amalgamation of distal phalanges in a knot-like structure, and second- and third-toe fusion. Some individuals present only with webbing between second and third toes, without involvement of fingers.


syndactyly type 4

description: A very rare congenital distal limb malformation characterized by complete bilateral syndactyly (involving all digits 1 to 5).


syndactyly type 8

description: Syndactyly type 8 is a rare, genetic, non-syndromic, congenital limb malformation characterized by unilateral or bilateral fusion of the fourth and fifth metacarpals with no other associated abnomalities. Patients present shortened fourth and fifth metacarpals with excessive separation between their distal ends, resulting in marked ulnar deviation of the little finger and an inability to bring the fifth finger in parallel with the other fingers.


synpolydactyly type 2

description: Any non-syndromic synpolydactyly in which the cause of the disease is a mutation in the FBLN1 gene.


syndactyly type 3

description: Syndactyly type 3 (SD3) is a rare congenital distal limb malformation characterized by complete and bilateral syndactyly between the 4th and 5th fingers.


TRIDECANAL

A long-chain fatty aldehyde that is tridecane in which two hydrogens attached to a terminal carbon are replaced by an oxo group.


chalcone biosynthetic process

description: The chemical reactions and pathways resulting in the formation of chalcone, phenyl steryl ketone or its hydroxylated derivatives.


name: familial avascular necrosis of femoral head

description: Avascular necrosis of femoral head (ANFH) is a severely disabling disease characterized by progressive groin pain, a limping gait, leg length discrepancy, collapse of the subchondral bone, limitation of hip function and eventual degeneration of the hip joint requiring total hip arthroplasty.


name: N-[2-(propan-2-ylamino)-1,3-benzodioxol-2-yl]carbamic acid ethyl ester


DIVALPROEX SODIUM

A mixture of valproic acid and its sodium salt in a 1:1 molar ratio. It is used for the management and treatment of seizure disorders, mania, and prophylactic treatment of migraine headache.


(+)-epigallocatechin

A flavan-3,3',4',5,5',7-hexol that has (2S,3S)-configuration.


A steroid acid that is 23,24-bisnor-chol-4-en-22-oic acid bearing additional oxo and hydroxy substituent at positions 3 and 9 respectively.


ureidoperacrylic acid

The peracid of ureidoacrylic acid where the acidic -OH group has been replaced by an -OOH group.


name: Advanced Malignant Small Intestinal Neoplasm

description: A malignant small intestinal neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.


name: Malignant neoplasm of small intestine, incl duodenum metastatic

description: A malignant small intestinal neoplasm that has spread from its original site of growth to another anatomic site.


name: Locally Advanced Small Intestinal Carcinoma

description: Small intestinal carcinoma that has spread to nearby tissues or lymph nodes.


name: Advanced Small Intestinal Small Cell Neuroendocrine Carcinoma

description: A small intestinal small cell neuroendocrine carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


name: Small intestine adenocarcinoma metastatic

description: An adenocarcinoma that arises from the small intestine and has metastasized to other anatomic sites.


name: Advanced Small Intestinal Neuroendocrine Carcinoma

description: A small intestinal neuroendocrine carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


name: Locally Advanced Small Intestinal Adenocarcinoma

description: Small intestinal adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Advanced Small Intestinal Large Cell Neuroendocrine Carcinoma

description: A small intestinal large cell neuroendocrine carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Small intestine carcinoma metastatic

description: A carcinoma that arises from the small intestine and it has metastasized to other anatomic sites.


name: Metastatic Small Intestinal Neuroendocrine Carcinoma

description: A small intestinal neuroendocrine carcinoma that has spread from its original site of growth to another anatomic site.


cidofovir dihydrate

The dihydrate of the anhydrous form of cidofovir. A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.


name: muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A14


myopathy caused by variation in GMPPB

description: Any myopathy in which the cause of the disease is a variation in the GMPPB gene.


name: muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B14


name: autosomal recessive limb-girdle muscular dystrophy type 2T

description: Autosomal recessive limb-girdle muscular dystrophy type 2T (LGMD2T) is a form of limb-girdle muscular dystrophy, that can present from birth to early childhood, characterized by hypotonia, microcephaly, mild proximal muscle weakness (leading to delayed walking and difficulty climbing stairs), mild intellectual disability and epilepsy. Additional manifestations reported in some patients include cataracts, nystagmus, cardiomyopathy, and respiratory insufficiency.


hexadecanal metabolic process

description: The chemical reactions and pathways involving hexadecanal, the C16 straight chain aldehyde.


hexadecanal biosynthetic process

description: The chemical reactions and pathways resulting in the formation of hexadecanal, the C16 straight chain aldehyde.


paneth cell of anorectum

category: biolink:Cell biolink:AnatomicalEntity biolink:PhysicalEssence biolink:OrganismalEntity biolink:SubjectOfInvestigation biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing biolink:PhysicalEssenceOrOccurrent

description: A paneth cell that is located in the anorectum.


epithelial cell of large intestine

description: An epithelial cell of the large intestine.


intestinal crypt stem cell of colon

description: An intestinal crypt stem cell that is located in the colon.


mesothelial cell of colon

description: A mesothelial cell that is part of the colon.


colon goblet cell

description: A goblet cell that is located in the colon.


name: microfold cell of epithelium proper of appendix

description: A M cell that is part of the epithelium proper of appendix.


name: epithelial cell of wall of inferior part of anal canal

description: An epithelial cell that is part of the wall of inferior part of anal canal.


type D cell of colon

description: A D cell located in the colon.


enterocyte of colon

description: A columnar cell of the colon that is part of the colonic epithelium.


large intestine goblet cell

description: A goblet cell that is part of the epithelium of large intestine.


glandular cell of the large intestine

description: A glandular epithelial cell of the large intestine.


rectum glandular cell

description: Glandular cell of rectal epithelium. Example: Goblet cell; enterocytes or absorptive cells; enteroendocrine and M cells.


enteroendocrine cell of appendix

description: An intestinal enteroendocrine cell that is located in a vermiform appendix.


colon glandular cell

description: Glandular cell of colon epithelium. Example: Goblet cells; enterocytes or absorptive cells; enteroendocrine and M cells.


epithelial cell of appendix

description: An epithelial cell that is part of the appendix.


appendix glandular cell

description: Glandular cell of appendix epithelium. Example: Goblet cells; enterocytes or absorptive cells; enteroendocrine and M cells.


name: enterocyte of epithelium proper of large intestine

description: An enterocyte that is part of the epithelium proper of large intestine.


epithelial cell of anal column

description: An epithelial cell of the anal column.


large intestine crypt goblet cell

description: A goblet cell that is part of the epithelium of crypt of Lieberkuhn of large intestine.


name: keratinized epithelial cell of the anal canal

description: An epithelial cell of the anal canal that is keratinized. This cell type is found towards the lower, rectal end of the anal canal.


name: microfold cell of epithelium proper of large intestine

description: A M cell that is part of the epithelium proper of large intestine.


name: enterocyte of epithelium of large intestine

description: Columnar cell which populate the epithelium of large intestine and absorb water. This cell is the most numerous of the epithelial cell types in the large intestine; bear apical microvilli, contain secretory granules in their apical cytoplasm; secretion appears to be largely mucins, but is also rich in antibodies of the IgA type.


name: microfold cell of epithelium proper of anorectum

description: A microfold cell (M cell) that is part of the anorectum.


enterocyte of appendix

description: An enterocyte that is a part of a vermiform appendix.


intestinal crypt stem cell of anorectum

description: An intestinal crypt stem cell that is located in the anorectum.


name: nonkeratinized epithelial cell of anal column

description: A nonkeratinized epithelial cell of the anal canal.


tuft cell of colon

description: A tuft cell that is a part of the colon.


name: intestinal crypt stem cell of large intestine

description: An intestinal stem cell that is located in the large intestine crypt of Liberkuhn. These stem cells reside at the bottom of crypts in the large intestine and are highly proliferative. They either differentiate into transit amplifying cells or self-renew to form new stem cells.


mesothelial cell of appendix

description: A mesothelial cell that is located in a vermiform appendix.


name: stratified squamous epithelial cell of anal canal

description: A stratified squamous epithelial cell that is part of the anal canal.


enteroendocrine cell of colon

description: An enteroendocrine cell that is located in the colon.


paneth cell of colon

description: A paneth cell that is located in the epithelium of the colon.


appendix goblet cell

description: A goblet cell that is part of the epithelium proper of appendix.


colon epithelial cell

description: Epithelial cell that is part of the colon epithelium.


intestinal crypt stem cell of appendix

description: An intestinal crypt stem cell that is located in the vermiform appendix. These stem cells reside at the bottom of crypts in the appendix and are highly proliferative. They either differentiate into transit amplifying cells or self-renew to form new stem cells.


name: nonkeratinized epithelial cell of inferior part of anal canal

description: A nonkeratinized cell epithleial cell of the inferior part of the anal canal.


tuft cell of anorectum

description: An intestinal tuft cell that is located in the anorectum.


enteroendocrine cell of anorectum

description: An enteroendocrine cell that is located in the anorectum.


anorectum goblet cell

description: A goblet cell that is located in the anorectum.


colon endothelial cell

description: A vascular endothelial cell found in colon blood vessels.


name: brush cell of epithelium proper of large intestine

description: Brush cell found in the epithelial layer of the colon.


paneth cell of the appendix

description: A paneth cell of the appendix.


name: COX deficiency, benign infantile mitochondrial myopathy

description: A cytochrome-c oxidase deficiency disease characterized by localization to tissues of the skeletal muscles.


cytochrome-c oxidase deficiency disease

description: A very rare inherited metabolic disorder characterized by deficiency of the enzyme cytochrome-C oxidase. It may be manifested as an isolated myopathy or a systemic disorder. Signs and symptoms include myotonia, dysfunction of the heart, kidney, and brain, and lactic acidosis.


glycolaldehyde triphosphate

A member of the class of aldehydes that is glycolaldehyde in which the hydroxy hydrogen has been replaced by a triphosphate group.


name: ENSAT Stage III Adrenal Cortical Carcinoma

description: Stage III includes: T3/T4, N0/N1, M0.  Tumor of any size that has spread to the fat outside the adrenal gland or into nearby organs or tissues and/or has spread to the regional lymph nodes. (ENSAT 7th Ed, 2009)


name: Adrenal Cortical Carcinoma by ENSAT Stage

description: A term that refers to the staging of adrenal cortical carcinoma according to the European Network for the Study of Adrenal Tumors (ENSAT).


name: ENSAT Stage I Adrenal Cortical Carcinoma

description: Stage I includes: T1, N0, M0.  Tumor 5 cm or less in greatest dimension. The tumor has not invaded the surrounding tissues or organs and has not spread to lymph nodes or distant organs or tissues.  (ENSAT 7th Ed, 2009)


name: ENSAT Stage II Adrenal Cortical Carcinoma

description: Stage II includes: T2, N0, M0. Tumor greater than 5 cm. The tumor has not invaded surrounding tissues or organs and has not spread to lymph nodes or distant organs or tissues. (ENSAT 7th Ed, 2009)


name: ENSAT Stage IV Adrenal Cortical Carcinoma

description: Stage IV includes: Any T, Any N, M1. Tumor of any size that involves distant organs such as liver, bone or brain. The tumor may or may not involve nearby organs, tissues or lymph nodes. (ENSAT 7th Ed, 2009)


name: renal hypoplasia, unilateral, non-human animal

description: Renal hypoplasia, unilateral that occurs in non-human animals.


renal hypoplasia, unilateral, pig

description: Renal hypoplasia, unilateral that occurs in pig.


pentaglycine

A pentapeptide comprised of five glycine residues.


negative regulation of TORC2 signaling

description: Any process that stops, prevents or reduces the frequency, rate or extent of TORC2 signaling.


positive regulation of TORC2 signaling

description: Any process that activates or increases the frequency, rate or extent of TORC2 signaling.


intein-mediated protein splicing

description: The removal of an internal amino acid sequence (an intein) from a protein during protein maturation; the excision of inteins is precise and the N- and C-terminal exteins are joined by a normal peptide bond. Protein splicing involves 4 nucleophilic displacements by the 3 conserved splice junction residues.


protein splicing

description: The post-translational removal of peptide sequences from within a protein sequence.


non-intein-mediated protein splicing

description: The post-translational removal of peptide sequences from within a protein sequence, by a process not involving inteins.


A 1,2-diacyl-sn-glycerol where butyryl and oleoyl are the 1- and 2-acyl groups respectively.


A 1,3-diglyceride in which the acyl groups at positions 1 and 3 are specified as palmitoyl and oleoyl respectively (the R-stereoisomer).


diacylglycerol 28:0

A diglyceride in which the two acyl groups contain a total of 28 carbons and 0 double bonds.


diacylglycerol 34:2

A diglyceride in which the two acyl groups contain a total of 34 carbons and 2 double bonds.


diacylglycerol 33:1

A diglyceride in which the two acyl groups contain a total of 33 carbons and 1 double bond.


A 1,2-diacyl-sn-glycerol where oleoyl and lauroyl are the 1- and 2-acyl groups respectively.


A 1,2-diacyl-sn-glycerol that has palmitoyl and tetradecanoyl as 1- and 2-acyl groups respectively.


A 2,3-diacyl-sn-glycerol that has oleoyl and lauroyl as the 2- and 3-acyl groups respectively.


A diacylglycerol 40:10 in which the acyl groups specified at positions 1 and 2 are (6Z,9Z,12Z,15Z)-octadecatetraenoyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively.


A diacylglycerol 38:2 in which the acyl groups specified at positions 1 and 2 are (9Z,12Z)-octadecadienoyl and  icosanoyl respectively.


A 1-alkyl-2-acylglycerol that has S-configuration.


diacylglycerol 34:0

A diglyceride in which the two acyl groups contain a total of 34 carbons and 0 double bonds.


A diacylglycerol 40:5 in which the acyl groups specified are  icosanoyl and (5Z,8Z,11ZZ,14Z,17Z)-eicosapentaenoyl respectively,


A  1,2-diglyceride with lauroyl and oleoyl as the two acyl groups.


diacylglycerol 36:3

A diglyceride in which the two acyl groups contain a total of 36 carbons and 3 double bonds.


A 1,2-diglyceride with stearoyl and oleoyl as the acyl groups.


A 1,2-diacyl-sn-glycerol where oleoyl and linoleoyl are the 1- and 2-acyl groups respectively.


A 1,2-diacyl-sn-glycerol that has palmitoyl and palmitoleoyl as 1- and 2-acyl groups respectively.


A 1,2-diacyl-sn-glycerol in which the acyl groups at positions 1 and 2 are specified as palmitoyl and arachidonoyl respectively.


A 1,2-diacyl-sn-glycerol with palmitoyl as the 1-acyl group and oleoyl as the 2-acyl group.


A glycerolipid where R1 is an alkyl or an acyl group, R2 is an acyl chain and R3 can be an H, a phosphate or a phospholipid group.


diacylglycerol 40:7

A diglyceride in which the two acyl groups contain a total of 40 carbons and 7 double bonds.


diacylglycerol 36:6

A diglyceride in which the two acyl groups contain a total of 36 carbons and 6 double bonds.


A 1,2-diglyceride with acyl groups at positions 2 and 3 of the sn-glycerol.


A  2,3-diacyl-sn-glycerol where oleoyl and arachidonoyl form the 2- and 3-acyl groups respectively.


A 1,2-diacyl-sn-glycerol in which the 1- and 2-acyl groups are specified as 12-hydroxy-(9Z)-octadecenoyl.


A 1,2-diacyl-sn-glycerol where oleoyl and decanoyl are the 1- and 2-acyl groups, respectively.


A 1,2-diacyl-sn-glycerol that has lauroyl and oleoyl as 1- and 2-acyl groups respectively.


diacylglycerol 33:2

A diglyceride in which the two acyl groups contain a total of 33 carbons and 2 double bonds.


dioleoylglycerol

A diglyceride in which both groups are oleoyl with their positions of acylation unspecified. Formula C39H72O5. For the structure shown, either R1 = H and R2 = oleoyl or R1 = oleoyl and R2 = H.


A 1,2-diacyl-sn-glycerol where oleoyl and stearoyl are the 1- and 2-acyl groups respectively.


A 1,2-diglyceride in which the acyl groups at positions 1 and 2 are specifed as stearoyl and arachidonoyl respectively.


diacylglycerol (18:1/18:2/0:0)

A 1,2-diglyceride in which the fatty acyl groups at positions 1 and 2 are specified as C18:1 and C18:2 respectively.


A 1,2-diacyl-sn-glycerol where oleoyl and arachidonoyl are the 1- and 2-acyl groups respectively.


dihexadecanoylglycerol

A diglyceride that is glycerol in which any two of the hydroxy groups have undergone formal esterification by condensation with hexadecanoic (palmitic) acid. Formula C35H68O5. For the structure shown, either R1 = H and R2 = hexadecanoyl or R1 = hexadecanoyl and R2 = H.


A 1,2-diglyceride in which the acyl groups at positions 1 and 2 are specified as (11Z)-octadecenoyl.


diacylglycerol (16:0/18:1/0:0)

A 1,2-diglyceride in which the fatty acyl groups at positions 1 and 2 are specified as C16:0 and C20:1 respectively.


A  1,2-diacyl-sn-glycerol where arachidonoyl and oleoyl form the 1- and 2-acyl groups respectively.


diacylglycerol 38:7

A diglyceride in which the two acyl groups contain a total of 38 carbons and 7 double bonds.


A 1,2-diglyceride with myristoyl and oleoyl as the two acyl groups.


diacylglycerol 36:1

A diglyceride  in which the two acyl groups contain a total of 36 carbons and 1 double bond.


A  1,2-diacyl-sn-glycerol where icosanoyl and oleoyl are the 1- and 2-acyl groups respectively.


SAG

A 1,2-diacyl-sn-glycerol in which the acyl groups at positions 1 and 2 are specifed as stearoyl and arachidonoyl respectively.


A 1,2-diacyl-sn-glycerol in which the acyl groups positions 1 and 2 are specified as alpha-linolenoyl and icosanoyl (arachidoyl) respectively.


A galactoglycerolipid that is 1,2-diacyl-3-beta-D-galactosyl-sn-glycerol in which the galactosyl moiety is acylated at position 6.


diacylglycerol 32:1

A diglyceride in which the two acyl groups contain a total of 32 carbons and 1 double bond.


diacylglycerol (18:0/18:1/0:0)

A 1,2-diglyceride in which the fatty acyl groups at positions 1 and 2 are specified as C18:0 and C18:1 respectively.


A 1,2-diacyl-sn-glycerol that has myristoyl and palmitoyl as 1- and 2-acyl groups respectively.


A 1,3-diglyceride in which both acyl groups are specified as linoleoyl.


diacylglycerol 26:0

A diglyceride in which the two acyl groups contain a total of 26 carbons and 0 double bonds.


diacylglycerol (16:0/20:1/0:0)

A 1,2-diglyceride in which the fatty acyl groups at positions 1 and 2 are specified as C16:0 and C18:1 respectively.


diacylglycerol 40:1

A diglyceride in which the two acyl groups contain a total of 40 carbons and 1 double bond.


diacylglycerol 36:5

A diglyceride in which the two acyl groups contain a total of 36 carbons and 5 double bonds.


diacylglycerol 36:2

A diglyceride in which the two acyl groups contain a total of 36 carbons and 2 double bonds.


diacylglycerol 34:1

A diglyceride in which the two acyl groups contain a total of 34 carbons and 1 double bond.


A 1,3-diglyceride in which both acyl groups are specified as palmitoleoyl.


diacylglycerol 38:2

A diglyceride in which the two acyl groups contain a total of 38 carbons and 2 double bonds.


diacylglycerol (18:0/22:6/0:0)

A 1,2-diglyceride in which the fatty acyl groups at positions 1 and 2 are specified as C18:0 and C22:6 respectively.


A  1,2-diacyl-sn-glycerol that has myristoyl and oleoyl as 1- and 2-acyl groups respectively.


diacylglycerol 36:4

A diglyceride in which the two acyl groups contain a total of 36 carbons and 4 double bonds.


A 2,3-diacyl-sn-glycerol in which both acyl groups are specified as stearoyl (octadecanoyl).


A 1,2-diacyl-sn-glycerol with myristoyl and palmitoleoyl as 1- and 2-acyl groups respectively.


A 1,2-diglyceride where linoleoyl and oleoyl are the two acyl groups.


A 1,2-diacyl-sn-glycerol in which the acyl groups at positions 1 and 2 are specified as 7Z,10Z,13Z,16Z-docosatetraenoyl.


A 1,2-diglyceride in which the 1- and 2-acyl groups are specified as oleoyl and palmitoyl respectively.


A 1,2-diacyl-sn-glycerol in which the 1- and 2-acyl groups are specified as palmitoleoyl and stearoyl respectively.


dioctanoylglycerol

A diglyceride obtained by acylation of any two hydroxy groups of glycerol by octanoic acid. Formula C19H36O5. For the structure shown, either R1 = H and R2 = octanoyl or R1 = octanoyl and R2 = H.


diacylglycerol (18:0/20:3/0:0)

A 1,2-diglyceride in which the fatty acyl groups at positions 1 and 2 are specified as C18:0 and C20:3 respectively.


diacylglycerol 30:0

A diglyceride in which the two acyl groups contain a total of 30 carbons and 0 double bonds.


A 1,2-diacyl-sn-glycerol that has stearoyl and oleoyl as the 1- and 2-acyl groups respectively.


A 1-alkyl-2-acyl-sn-glycerol in which the alkyl and acyl groups are specified as palmityl (hexadecyl) and arachidonoyl respectively.


A 1,2-diacyl-sn-glycerol in which the 1- and 2-acyl groups are specified as palmitoleoyl.


A 2,3-diacyl-sn-glycerol that has  oleoyl and myristoyl as 2- and 3-acyl groups respectively.


diacylglycerol 35:3

A diglyceride in which the two acyl groups contain a total of 35 carbons and 3 double bonds.


A diglyceride in which both groups are (10Z)-heptadecenoyl with their positions of acylation unspecified. For the structure shown, either R1 = H and R2 = (10Z)-heptadecenoyl or R1 = (10Z)-heptadecenoyl and R2 = H.


A 1,2-diacyl-sn-glycerol in which the acyl groups positions 1 and 2 are specified as alpha-linolenoyl and (11Z,14Z)-icosadienoyl respectively.


A diacylglycerol having two docosahexaenoyl chains at undefined sn positions


A 2,3-diacyl-sn-glycerol in which the 2- and 3-acyl groups are both specified as oleoyl.


A dibutyrin resulting from the condensation the secondary hydroxy group and one of the primary hydroxy groups of glycerol with butyric acid.


A diacylglycerol 40:0 in which the acyl groups at positions 1 and 2 are octadecanoyl and docosanoyl respectively.


A 1,2-diacyl-sn-glycerol where both acyl groups are specified as octadecanoyl.


diacylglycerol 40:0

A diglyceride in which the acyl groups  contain a total of 40 carbons and 0 double bonds.


1,2 ditetradecanoylglycerol

A 1,2-diglyceride  in which the acyl groups at positions 1 and 2 are specifed as tetradecanoyl.


A 2,3-diacyl-sn-glycerol that has oleoyl and stearoyl as the 2- and 3-acyl groups respectively.


A 1,2-diacyl-sn-glycerol in which the 1- and 2-acyl groups are specified as capryl (decanoyl) and oleoyl (9Z-octadecenoyl) respectively.


diacylglycerol 34:3

A diglyceride in which the two acyl groups contain a total of 34 carbons and 3 double bonds.


diacylglycerol 36:0

A diglyceride in which the two acyl groups contain a total of 36 carbons and 0 double bonds.


diacylglycerol 32:2

A diglyceride in which the two acyl groups contain a total of 32 carbons and 2 double bonds.


A 2,3-diacyl-sn-glycerol in which both acyl groups are specified as palmitoyl (hexadecanoyl).


diacylglycerol 46:7

A diglyceride in which the two acyl groups contain a total of 46 carbons and 7 double bonds.


A 1-alkyl-2-acyl-sn-glycerol in which the alkyl and acyl groups are specified as palmityl (hexadecyl) and oleoyl respectively.


A diacylglycerol 38:0 in which the acyl groups specified at positions 1 and 2 are hexadecanoyl and docosanoyl respectively.


A 1,3-diglyceride in which the acyl groups at positions 1 and 3 are specified as oleoyl and linoleoyl respectively.


diacylglycerol 34:5

A diglyceride in which the two acyl groups contain a total of 34 carbons and 5 double bonds.


diacylglycerol 40:5

A diglyceride in which the acyl groups contain a total of 40 carbons and 5 double bonds.


A 1,2-diacyl-sn-glycerol where oleoyl and myristoyl are the 1- and 2-acyl groups respectively.


A 1,2-diacyl-sn-glycerol where alpha-linolenoyl and oleoyl form the 1- and 2-acyl groups respectively.


A 2,3-diacyl-sn-glycerol in which both the 2- and 3-acyl groups are specified as octanoyl.


A 1,3-diglyceride in which both acyl groups are specified as linolenoyl.


A 1,2-diacyl-sn-glycerol in which the acyl groups at positions 1 and 2 are specified as palmitoyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively.


dibutyrin

A diglyceride resulting from the formal condensation of any two of the hydroxy groups of glycerol with the carboxy groups of two molecules of butanoic acid (either R1 = H and R2 = butanoyl, or R1 = butanoyl and R2 = H). A 'closed class'.


diacylglycerol 38:5

A diglyceride in which the two acyl groups contain a total of 38 carbons and 5 double bonds.


diacylglycerol (18:1/20:4/0:0)

A 1,2-diglyceride in which the fatty acyl groups at positions 1 and 2 are specified as C18:1 and C20:4 respectively.


A 1,2-diacyl-sn-glycerol where linoleoyl and oleoyl form the 1- and 2-acyl groups respectively.


diacylglycerol (16:0/22:6/0:0)

A 1,2-diglyceride in which the fatty acyl groups at positions 1 and 2 are specified as C16:0 and C22:6 respectively.


A 1,2-diacyl-sn-glycerol in which the acyl groups at positions 1 and 2 are specified as oleoyl and gondoyl respectively.


A 1,2-diglyceride in which the acyl groups at positions 1 and 2 are specified as decanoyl and oleoyl respectively.


A 1,2-diacyl-sn-glycerol in which the acyl groups at positions 1 and 2 are specified as stearoyl and 7Z,10Z,13Z,16Z-docosatetraenoyl respectively.


A diacylglycerol where the acyl group at sn-1 or sn-3 is palmitoyl and the acyl group at position sn-2 is unkown.


diacylglycerol 38:9

A diglyceride in which the two acyl groups contain a total of 38 carbons and 9 double bonds.


diacylglycerol (18:1/0:0/18:1)

A 1,3-diglyceride in which both acyl groups contain 18 carbons and 1 double bond.


A 1,3-diglyceride in which the acyl groups at positions 1 and 3 are specified as oleoyl and palmitoyl respectively.


A 1,2-diglyceride with palmitoyl and oleoyl as the two acyl groups.


dipalmitoleoylglycerol

A diglyceride in which both groups are palmitoleoyl with their positions of acylation unspecified. For the structure shown, either R1 = H and R2 = palmitoleoyl or R1 = palmitoleoyl and R2 = H.


diacylglycerol (18:0/20:4/0:0)

A 1,2-diglyceride in which the fatty acyl groups at positions 1 and 2 are specified as C18:0 and C20:4 respectively.


A  2,3-diacyl-sn-glycerol where oleoyl and alpha-linolenoyl form the 2- and 3-acyl groups respectively.


A 1,2-diglyceride where arachidonoyl and oleoyl are the two acyl groups.


A 1,3-diglyceride in which the acyl groups at positions 1 and 3 are specified as oleoyl and palmitoyl respectively (the S-stereoisomer).


A 1,2-diacyl-sn-glycerol in which both the acyl groups are specified as hexadecadienoyl (the position of the two double bonds is unspecified).


diacetin

A diglyceride resulting from the formal condensation of any two of the hydroxy groups of glycerol with the carboxy groups of two molecules of acetic acid (either R1 = H and R2 = Ac, or R1 = Ac and R2 = H).


diacylglycerol 42:11

A diglyceride in which the two acyl groups contain a total of 42 carbons and 11 double bonds.


A 1,3-diglyceride in which the 1- and 3-acyl groups are specified as palmitoyl and stearoyl respectively (the R-enantiomer).


diacylglycerol 30:1

A  diglyceride in which the two acyl groups contain a total of 30 carbons and 1 double bonds.


diacylglycerol 41:5

A diglyceride in which the two acyl groups contain a total of 41 carbons and 5 double bonds.


diacylglycerol 28:2

A diglyceride in which the two acyl groups contain a total of 28 carbons and 2 double bonds.


A 1,2-diacyl-sn-glycerol in which the acyl groups positions 1 and 2 are specified as alpha-linolenoyl and (8Z,11Z,14Z)-icosatrienoyl respectively.


A 2,3-diacyl-sn-glycerol in which both acyl groups are specified as caproyl (hexanoyl).


A 1,2-diacyl-sn-glycerol in which both acyl groups are tetradecanoyl (myristoyl).


diacylglycerol 28:1

A diglyceride in which the two acyl groups contain a total of 28 carbons and 1 double bond.


A dibutyrin resulting from the condensation of both of the primary hydroxy groups of glycerol with butyric acid.


diacylglycerol 38:6

A diglyceride in which the two acyl groups contain a total of 38 carbons and 6 double bonds.


A 1-alkyl-2-acyl-sn-glycerol in which the 1-alkyl substituent can be any alk-1-enyl group.


diacylglycerol 40:10

A diglyceride in which the acyl groups contain a total of 40 carbon atoms and 0 double bonds.


A 1,2-diacyl-sn-glycerol in which the 1- and 2-acyl groups are specified as palmitoleoyl and linoleoyl respectively.


A 2,3-diacyl-sn-glycerol in which both acyl groups are specified as myristoyl (tetradecanoyl).


diacylglycerol 38:4

A diglyceride in which the two acyl groups contain a total of 38 carbons and 4 double bonds.


A 1,3-diglyceride obtained by the formal acylation of positions 1 and 3 of glycerol by hexadecanoic (palmitic) acid.


diacylglycerol 44:12

A diglyceride in which the two acyl groups contain a total of 44 carbons and 12 double bonds.


diacylglycerol 34:4

A diglyceride in which the two acyl groups contain a total of 34 carbons and 4 double bonds.


diacylglycerol 41:1

A diglyceride in which the two acyl groups contain a total of 41 carbons and 1 double bond.


diacylglycerol 30:2

A diglyceride in which the two acyl groups contain a total of 30 carbons and 2 double bonds.


A 1,3-diglyceride in which both acyl groups are specified as octanoyl.


diacylglycerol 42:10

A diglyceride in which the two acyl groups contain a total of 42 carbons and 10 double bonds.


A diacylglycerol 34:1 in which the acyl groups specified at positions 1 and 2 are (11Z)-octadecenoyl and hexadecanoyl respectively.


diacylglycerol (16:0/22:4/0:0)

A 1,2-diglyceride in which the fatty acyl groups at positions 1 and 2 are specified as C16:0 and C22:4 respectively.


A diacylglycerol 34:0 in which the acyl groups specified at positions 1 and 2 are hexadecanoyl and octadecanoyl respectively.


A 2,3-diacyl-sn-glycerol in which both acyl groups are specified as palmitoleoyl.


diacylglycerol 37:1

A diglyceride in which the two acyl groups contain a total of 37 carbons and 1 double bond.


A 1,2-diacyl-sn-glycerol in which the 1- and 2-acyl groups are specified as palmitoyl and (11Z,14Z)-eicosadienoyl respectively.


diacylglycerol (18:0/22:5/0:0)

A 1,2-diglyceride in which the fatty acyl groups at positions 1 and 2 are specified as C18:0 and C22:5 respectively.


A 1,2-diacyl-sn-glycerol in which both acyl groups are specified as palmitoyl (hexadecanoyl).


A 1,3-diglyceride with both acyl groups specified as oleoyl.


diacylglycerol 40:8

A diglyceride in which the acyl groups contain a total of 40 carbons and 8 double bonds.


palmitoylacylglycerol

A diacylglycerol with an undefined acyl group at position sn-1 or sn-3 and a palmitoyl group at an undefined position.


diacylglycerol 40:4

A diglyceride in which the two acyl groups contain a total of 40 carbons and 4 double bonds.


A 1,2-diacyl-sn-glycerol in which the acyl groups positions 1 and 2 are specified as alpha-linolenoyl and (11Z)-icosenoyl respectively.


dipropionin

A diglyceride resulting from the formal condensation of any two of the hydroxy groups of glycerol with the carboxy groups of two molecules of propionic acid (either R1 = H and R2 = propanoyl, or R1 = propanoyl and R2 = H).


diacylglycerol 38:3

A diglyceride in which the two acyl groups contain a total of 38 carbons and 3 double bonds.


A 1,2-diglyceride in which the acyl groups at positions 1 and 2 are specified as (9Z)-hexadecenoyl.


A 1,2-diacyl-sn-glycerol in which the 1- and 2-acyl groups are specified as oleoyl and alpha-linolenoyl respectively.


A 1,2-diacyl-sn-glycerol that has pentadecanoyl as 1- and 2-acyl groups.


A 1,2-diacyl-sn-glycerol in which the 1- and 2-acyl groups are specified as palmitoyl and (7Z,10Z,13Z,16Z)-docosatetraenoyl  respectively.


A 1,2-diglyceride with linolenoyl and oleoyl as the two acyl groups.


A 2,3-diacyl-sn-glycerol in which both acyl groups are specified as linoleoyl.


A 1,2-diacyl-sn-glycerol in which both the acyl groups are specified as (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl.


diacylglycerol (16:0/20:4/0:0)

A 1,2-diglyceride in which the fatty acyl groups at positions 1 and 2 are specified as C16:0 and C20:4 respectively.


SLG

A 1,2-diacyl-sn-glycerol in which the acyl groups at positions 1 and 2 are specified as stearoyl and linoleoyl respectively.


diacylglycerol 32:0

A diglyceride in which the two acyl groups contain a total of 32 carbons and 0 double bond.


diacylglycerol 38:0

A diglyceride in which the acyl groups contain a total of 38 carbons and 0 double bonds.


A 1,3-diglyceride with acyl groups at positions 1 and 3 of sn-glycerol.


A diacylglycerol 36:0 in which both acyl group contain 18 carbons.


A 1,2-diacyl-sn-glycerol in which the acyl groups at positions 1 and 2 are specified as (9Z,12Z)-octadecadienoyl and octadecanoyl respectively.


A 1,2-diacyl-sn-glycerol in which the acyl groups positions 1 and 2 are specified as alpha-linolenoyl and (5Z,8Z,11Z)-icosatrienoyl respectively.


diacylglycerol 35:0

A diglyceride in which the two acyl groups contain a total of 35 carbons and 0 double bonds.


A 1,2-diacyl-sn-glycerol in which the acyl groups at positions 1 and 2 are specified as oleoyl.


A 1,2-diglyceride obtained by the formal acylation of positions 1 and 2 of glycerol by hexadecanoic (palmitic) acid.


A 1,2-diacyl-sn-glycerol where octanoyl and oleoyl form the 1- and 2-acyl groups respectively.


diacylglycerol (18:0/22:4/0:0)

A 1,2-diglyceride in which the fatty acyl groups at positions 1 and 2 are specified as C18:0 and C22:4 respectively.


A 2,3-diacyl-sn-glycerol where oleoyl and linoleoyl form the 2- and 3-acyl groups respectively.


diacylglycerol 32:3

A diglyceride in which the two acyl groups contain a total of 32 carbons and 3 double bonds.


A 2,3-diacyl-sn-glycerol with oleoyl as 2-acyl group and palmitoyl as the 3-acyl group.


diacylglycerol 31:1

A diglyceride in which the two acyl groups contain a total of 31 carbons and 1 double bond.


diacylglycerol 38:1

A diglyceride in which the two acyl groups contain a total of 38 carbons and 1 double bond.


A 1,2-diacyl-sn-glycerol in which the acyl groups at positions 1 and 2 are both myristoleoyl groups.


DOG

1,2-diacyl-sn-glycerol in which both the 1- and 2-acyl groups are specified as octanoyl. Formula C19H36O5.


diacylglycerol 33:3

A diglyceride in which the two acyl groups contain a total of 33 carbons and 3 double bonds.


A 1-(alk-1-enyl)-2-acyl-sn-glycerol in which the alk-1-enyl group has Z geochemistry.


diacylglycerol 40:6

A diglyceride in which the two acyl groups contain a total of 40 carbons and 6 double bonds.


A diacylglycerol 34:0 in which one acyl group contains 18 carbons the other, 16 carbons


dilinoleoylglycerol

A diglyceride that is glycerol in which any two of the hydroxy groups have undergone formal esterification by condensation with linoleic acid ((Z,Z)-octadeca-9,12-dienoic acid). Formula C39H68O5. For the structure shown, either R1 = H and R2 = linoleoyl or R1 = linoleoyl and R2 = H.


A 1,2-diacyl-sn-glycerol in which the acyl groups at positions 1 and 2 are specified as oleoyl and 7Z,10Z,13Z,16Z-docosatetraenoyl respectively.


A 1,2-diacyl-sn-glycerol in which both acyl groups are specified as linoleoyl.


A diacyl-sn-glycerol with palmitoyl as the 1-acyl group and oleoyl with its position of acylation unspecified. For the structure shown, either R1 = H and R2 = oleoyl or R1 = oleoyl and R2 = H.


A 1,2-diacyl-sn-glycerol in which the acyl groups at positions 1 and 2 are specified as oleoyl and 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl respectively.


A 1,3-diglyceride in which the acyl groups at positions 1 and 3 are specified as palmitoyl (hexadecanoyl) and linoleoyl respectively.


A 2,3-diacyl-sn-glycerol in which the acyl groups at positions 2 and 3 are specified as palmitoyl and oleoyl respectively.


diacylglycerol 40:3

A diglyceride in which the two acyl groups contain a total of 40 carbons and 3 double bonds.


diacylglycerol 35:1

A diglyceride in which the two acyl groups contain a total of 35 carbons and 1 double bond.


A 1,2-diacyl-sn-glycerol in which the acyl groups at positions 1 and 2 are specified as icosanoyl (arachidoyl) and arachidonoyl respectively.


A 1,2-diacyl-sn-glycerol in which the 1- and 2-acyl groups are specified as palmitoyl and (8Z,11Z,14Z-eicosatrienoyl respectively.


diacylglycerol (18:1/22:4/0:0)

A 1,2-diglyceride in which the fatty acyl groups at positions 1 and 2 are specified as C18:1 and C22:4 respectively.


diarachidonoylglycerol

A diacylglycerol having two arachidonoyl chains at undefined sn positions


A 1,3-diglyceride in which both acyl groups contain 18 carbons and 2 double bonds.


A 1,2-diacyl-sn-glycerol in which the acyl groups at positions 1 and 2 are specified as oleoyl and 8Z,11Z,14Z-eicosatrienoyl respectively.


A beta-D-galactosyl-(1->4)-beta-D-glucosylceramide where the ceramide N-acyl group is specified as hexacosanoyl.


name: trichorhinophalangeal syndrome, type III

description: A trichorhinophalangeal syndrome caused by mutations in TRPS1 characterized by the presence of severe brachydactyly, due to short metacarpals, and severe short stature.


methyl tert-butyl ether

An ether having methyl and tert-butyl as the two alkyl components.


tricin 7-O-beta-D-glucoside

A glycosyloxyflavone that is 3',5'-di-O-methyltricetin (tricin) in which the phenolic hydrogen at position 7 has been replaced by a beta-D-glucopyranosyl group.


name: round cell sarcoma with EWSR1-NFATC2 gene fusion

description: A round cell sarcoma with EWSR1-non-ETS fusion that is characterized by the presence of EWSR1-NFATC2 gene fusion.


name: peptidoglycan-protein cross-linking via N6-mureinyl-L-lysine

description: The process of linking a protein to peptidoglycan via the epsilon amino group of lysine to the diaminopimelic acid of the peptidoglycan.


peptidoglycan metabolic process

description: The chemical reactions and pathways involving peptidoglycans, any of a class of glycoconjugates found only in bacterial cell walls and consisting of strands of glycosaminoglycan cross-linked by oligopeptides to form a huge and rigid network.


peptidoglycan turnover

description: The continual breakdown and regeneration of peptidoglycan required to maintain the cell wall.


galactosaminoglycan metabolic process

description: The chemical reactions and pathways involving galactosaminoglycans, any one of a group of polysaccharides that contain amino sugars derived from the galactose.


mucopolysaccharide metabolic process

description: The chemical reactions and pathways involving mucopolysaccharide.


peptidoglycan biosynthetic process

description: The chemical reactions and pathways resulting in the formation of peptidoglycans, any of a class of glycoconjugates found in bacterial cell walls.


name: peptidoglycan-protein cross-linking via L-threonyl-pentaglycyl-murein

description: The process of linking a protein to peptidoglycan via a carboxy terminal threonine carboxyl group through a pentaglycyl peptide to the lysine or diaminopimelic acid of the peptidoglycan.


heparin metabolic process

description: The chemical reactions and pathways involving heparin, any member of a group of glycosaminoglycans found mainly as an intracellular component of mast cells. They are similar to heparan sulfates but are of somewhat higher average Mr (6000-20000) and contain fewer N-acetyl groups and more N-sulfate and O-sulfate groups; they may be attached in the same manner to protein, forming proteoglycans. They consist predominantly of alternating alpha-(1->4)-linked D-galactose and N-acetyl-D-glucosamine-6-sulfate residues.


glycosaminoglycan biosynthetic process

description: The chemical reactions and pathways resulting in the formation of glycosaminoglycans, any of a group of polysaccharides that contain amino sugars.


name: peptidoglycan-protein cross-linking via L-alanyl-pentaglycyl-murein

description: The process of linking a protein to peptidoglycan via a carboxy terminal alanine carboxyl group through a pentaglycyl peptide to the lysine or diaminopimelic acid of the peptidoglycan.


description: The chemical reactions and pathways resulting in the formation of galactosaminoglycans, any of a group of polysaccharides that contain amino sugars derived from the galactose.


name: protein-chondroitin sulfate linkage via chondroitin sulfate D-glucuronyl-D-galactosyl-D-galactosyl-D-xylosyl-L-serine

description: Chondroitin sulfate components are covalently linked to a core glycoprotein via O-glycosidic linkages between xylose and serine residues.


peptidoglycan-protein cross-linking

description: The process of covalently linking peptidoglycan (murein) to proteins.


name: 2-[(2R,3R,6S)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester


urolithiasis, pig

description: Urolithiasis that occurs in pig.


name: autosomal dominant nonsyndromic hearing loss 65

description: Any autosomal dominant nonsyndromic deafness in which the cause of the disease is a mutation in the TBC1D24 gene.


Probable Acute COVID-19 Case

description: A presumed acute COVID-19 infection as evidenced by detection of SARS-CoV-2 by antigen test in a respiratory specimen, by meeting clinical criteria and epidemiological linkage criteria for COVID-19 with no confirmatory laboratory testing performed, or by a death certificate that lists COVID-19 disease or SARS-CoV-2 as an underlying cause of death or a significant condition contributing to death with no confirmatory laboratory evidence of SARS-CoV-2.


Coronavinae infectious disease

description: Virus diseases caused by the coronavirus genus. Some specifics include transmissible enteritis of turkeys (enteritis, transmissible, of turkeys); feline infectious peritonitis; and transmissible gastroenteritis of swine (gastroenteritis, transmissible, of swine).


name: Pulmonary Thromboembolic Disease Associated with Post-Acute Sequelae of SARS-CoV-2 Infection

description: Intravascular migration of a venous embolus to the pulmonary arterial circulation, microvascular thrombosis in the pulmonary capillaries, or pulmonary artery thrombus in situ diagnosed by a positive pulmonary angiogram, an unequivocally positive helical CT scan, a high-probability ventilation-perfusion scan, or autopsy that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.


name: Post-Acute Cardiovascular Sequelae of COVID-19

description: Cardiovascular sequelae persisting weeks or months after SARS-CoV-2 infection.


name: Supraventricular Tachyarrhythmia Other than Atrial Fibrillation or Atrial Flutter Associated with Post-Acute Sequelae of SARS-CoV-2 Infection

description: Supraventricular tachycardia other than atrial fibrillation or atrial flutter in a patient without prior history of atrial tachyarrhythmias that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.


name: Ischemic Cardiomyopathy Associated with Post-Acute Sequelae of SARS-CoV-2 Infection

description: Reduced left ventricular function with less than 50% ejection fraction in a patient with history of suspected or confirmed myocardial ischemia or acute coronary syndrome (ACS) that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.


long COVID-19

description: A chronic disease triggered by acute COVID-19 infection that is characterized by persistent symptoms following the acute phase of the SARS-CoV-2 infection, which may include fatigue, coughing, dyspnea, clouding of mentation, sleep disturbances, exercise intolerance and autonomic symptoms including tachycardia upon mild exercise or standing, night sweats, temperature dysregulation, gastroparesis, constipation or loose stools, and peripheral vasoconstriction.


name: Atrial Flutter Associated with Post-Acute Sequelae of SARS-CoV-2 Infection

description: Atrial flutter in a patient without prior history of atrial tachyarrhythmias that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.


name: Symptomatic COVID-19 Infection Laboratory-Confirmed

description: An infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is symptomatic at the time of testing.


name: Pericarditis Associated with Post-Acute Sequelae of SARS-CoV-2 Infection

description: Pericarditis that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.


Confirmed Acute COVID-19 Case

description: An acute COVID-19 infection that is verified by detection of SARS-CoV-2 RNA in a clinical or autopsy specimen using a molecular amplification test (e.g., RT-PCR).


name: Pericardial Effusion Associated with Post-Acute Sequelae of SARS-CoV-2 Infection

description: Pericardial effusion that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.


name: Atrial Fibrillation Associated with Post-Acute Sequelae of SARS-CoV-2 Infection

description: Atrial fibrillation in a patient without prior history of atrial tachyarrhythmias that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.


Severe COVID-19 Infection

description: An infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) where the individual is hospitalized, requires respiratory support, and may also require additional organ support including vasopressor therapy, renal replacement therapy, or extracorporeal membrane oxygenation. (based on WHO COVID-19 Disease Severity 5, 6 and 7)


name: Asymptomatic COVID-19 Infection Laboratory-Confirmed

description: An infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is asymptomatic at the time of testing.


Middle East respiratory syndrome

description: A viral respiratory infection that is caused by the MERS coronavirus (MERS-CoV), which most often manifests with moderate to severe respiratory symptoms, including productive cough and shortness of breath, which can progress to pneumonia and acute respiratory distress syndrome.


name: Cardiac Structural Abnormalities Associated with Post-Acute Sequelae of SARS-CoV-2 Infection

description: Cardiac structural changes or abnormalities characterized by myocardial systolic dysfunction or myocardial edema or fibrosis on non-invasive cardiac imaging that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.


name: New-onset Heart Failure Associated with Post-Acute Sequelae of SARS-CoV-2 Infection

description: New onset of heart failure with a clinical syndrome of dyspnea, fatigue, fluid retention/peripheral edema that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.


Suspected Acute COVID-19 Case

description: A likely acute COVID-19 infection as evidenced by detection of specific antibody in serum, plasma, or whole blood, or detection of specific antigen by immunocytochemistry in an autopsy specimen.


name: Prior COVID-19 Infection With Residual Sequelae of Post-Acute COVID-19

description: A finding indicating that there is prior evidence of COVID-19 in an individual who has residual sequelae of post-acute COVID-19.


Moderate COVID-19 Infection

description: An infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) where the individual is hospitalized and may require oxygen therapy. (based on WHO COVID-19 Disease Severity 3 and 4)


name: Prior COVID-19 Infection Without Residual Sequelae of Post-Acute COVID-19

description: A finding indicating that there is prior evidence of COVID-19 in an individual who has no residual sequelae of post-acute COVID-19.


Mild COVID-19 Infection

description: An infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) where the individual is still ambulatory but may have limitation of their activities. (based on WHO COVID-19 Disease Severity 1 and 2)


name: Neurovascular Disorder Associated with Post-Acute Sequelae of SARS-CoV-2 Infection

description: A disorder of the nervous system related to a vascular etiology that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.


name: Deep Venous Thrombosis Associated with Post-Acute Sequelae of SARS-CoV-2 Infection

description: Formation of multiple thrombi in the large veins of the body, diagnosed with Doppler ultrasound, occurring most frequently in lower extremities or upper extremities, that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.


COVID Reinfection

description: A new, discrete episode of acute COVID-19 in an individual with a prior history of probable/confirmed COVID-19.


name: Non-Ischemic Cardiomyopathy Associated with Post-Acute Sequelae of SARS-CoV-2 Infection

description: Reduced left ventricular function with less than 50% ejection fraction but without evidence of myocardial ischemia that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.


Current Seasonal Coronavirus Infection

description: Seasonal coronavirus infection is evident at the time of testing.


Prior COVID-19 Infection

description: A finding indicating that there is prior evidence of COVID-19 in an individual who is no longer in the infectious period.


chromosome Y disorder

description: Chromosomal disorder in which chromosome Y is affected.


isochromosomy Yq

description: Isochromosomy Yq is a rare gonosomy anomaly with a variable phenotype including a female phenotype with sexual development delay, streak gonads, short stature and Turner syndrome features and male phenotype with infertility due to azoospermia.


spermatogenic failure, Y-linked, 2

description: A Y-linked genetic condition caused by mutation(s) in the USP9Y gene, encoding probable ubiquitin carboxyl-terminal hydrolase FAF-Y.  It is associated with male infertility secondary to nonobstructive azoospermia and hypospermatogenesis.


48,XYYY syndrome

description: 48,XYYY syndrome is a rare Y chromosome number anomaly that affects only males and is characterized by mild-moderate developmental delay (especially speech), normal to mild intellectual disability, large, irregular teeth with poor enamel, tall stature and acne. Radioulnar stenosis and clinodactyly have also been associated. Boys generally present normal genitalia, while hypogonadism and infertility is frequently reported in adult males.


partial chromosome Y deletion

description: Male sterility due to chromosome Y deletion is characterized by a severe deficiency of spermatogenesis. Chromosome Y deletions are a frequent genetic cause of male infertility.


ring chromosome Y

description: Ring chromosome Y is a rare chromosome Y structural anomaly, with a highly variable phenotype, mostly characterized by short stature, partial to total gonadal failure, sexual infantilism, genital anomalies (e.g. ambiguous genitalia, hypospadias, cryptorchidism), and azoospermia or oligozoospermia. Additional reported features include speech delay, obesity, and acanthosis nigricans. Gender dysphoria and comorbid bipolar disorder have also been observed.


49,XYYYY syndrome

description: 49,XYYYY is a rare Y chromosome number anomaly with a variable phenotype mainly characterized by moderate to severe intellectual disability, speech delay, hypotonia, and mild dysmorphic features, including facial asymmetry, hypertelorism, bilateral low set 'lop' ears, and micrognatia. Skeletal abnormalities (such as skull deformities, radioulnar synostosis, elbow flexion, clinodactyly, brachydactyly) and behavourial problems have also been associated with this condition. Genitalia are normal at birth, although hypogonadism and azoospermia has been reported in adults.


isochromosomy Yp

description: Isochromosomy Yp is a rare gonosome anomaly characterized by various clinical presentations including normal healthy fertile males, male phenotype with infertility, and males with ambiguous genitalia or incomplete masculinization.


Conjugate base of bkas#26-CoA


cAMP biosynthetic process

description: The chemical reactions and pathways resulting in the formation of the nucleotide cAMP (cyclic AMP, adenosine 3',5'-cyclophosphate).


DNA transposition

description: A type of transposition in which a transposable element (transposon) is moved to another part of a genome, either by a cut-and-paste mechanism or a replicative mechanism.


non-replicative DNA transposition

description: Process by which a transposable element is excised from the donor site and integrated at the target site without replication of the element. Also referred to as cut-and-paste transposition.


replicative DNA transposition

description: Process of transposition in which the existing element is replicated and one of the copies is excised and integrated at a new target site. Also referred to as copy-and-paste transposition.


name: Pancreatic Well Differentiated Ductal Adenocarcinoma

description: A pancreatic ductal adenocarcinoma characterized by the presence of duct-like structures and medium-sized malignant glandular structures.


Stage M3 Pineoblastoma

description: Gross nodular seeding is detected in the spinal subarachnoid space. (Chang CH, Housepian EM, Herbert C. Radiology, 1969; 93(6):1351-9.)


cellular response to iron(II) ion

description: Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an iron(II) ion stimulus.


name: negative regulation of chemorepellent activity

description: Any process that stops, prevents or reduces the frequency, rate or extent of chemorepellent activity.


name: positive regulation of chemorepellent activity

description: Any process that activates or increases the frequency, rate or extent of chemorepellent activity.


dysthymic disorder

description: A chronic mood disorder in which the symptoms are similar to, though milder than, those diagnosed in depression.


(R,R)-asenapine

A 5-chloro-2-methyl-2,3,3a,12b-tetrahydrodibenzo[2,3:6,7]oxepino[4,5-c]pyrrole in which both of the stereocentres have R configuration.


Notch receptor processing

description: The series of successive proteolytic cleavages of the Notch protein, which result in an active form of the receptor.


(3R,5S)-fluvastatin sodium

An organic sodium salt resulting from the replacement of the proton from the carboxy group of (3R,5S)-fluvastatin by a sodium ion.


(R)-warfarin sodium

An organic sodium salt having 2-oxo-3-[(1R)-3-oxo-1-phenylbutyl]-2H-1-benzopyran-4-olate as the counterion (the racemate is warfarin sodium, an anticoagulant drug and rodenticide).


TABERSONINE

A monoterpenoid indole alkaloid with cytotoxic activity.


name: negative regulation of TRAIL-activated apoptotic signaling pathway

description: Any process that stops, prevents or reduces the frequency, rate or extent of TRAIL-activated apoptotic signaling pathway.


name: L-methionine biosynthetic process from homoserine via O-succinyl-L-homoserine and cystathionine

description: The chemical reactions and pathways resulting in the formation of L-methionine from other compounds, including homoserine, via the intermediates O-succinyl-L-homoserine and cystathionine.


Childhood Cutaneous Melanoma

description: A rare melanoma of the skin that occurs during childhood.


N-acetyl-D-galactosaminic acid

A carbohydrate acid derivative comprising D-galactonic acid having the 2-hydroxy group replaced by acetamido.


description: The chemical reactions and pathways involving poly(5-hydroxyvalerate).


description: The chemical reactions and pathways involving poly(hydroxyalkanoate).


description: The chemical reactions and pathways resulting in the formation of poly(3-hydroxyvalerate).


description: The chemical reactions and pathways resulting in the formation of poly(5-hydroxyvalerate).


description: The chemical reactions and pathways resulting in the formation of poly-hydroxybutyrate (PHB), a polymer of beta-hydroxybutyrate and a common storage material of prokaryotic cells.


poly(hydroxyvalerate) metabolic process

description: The chemical reactions and pathways involving poly(hydroxyvalerate).


description: The chemical reactions and pathways involving poly(3-hydroxyvalerate).


name: poly(hydroxyalkanoate) biosynthetic process from glucose

description: The chemical reactions and pathways resulting in the formation of poly(hydroxyalkanoate) from glucose.


poly-hydroxybutyrate metabolic process

description: The chemical reactions and pathways involving poly-hydroxybutyrate (PHB), a polymer of beta-hydroxybutyrate and a common storage material of prokaryotic cells.


name: poly(hydroxyalkanoate) biosynthetic process from fatty acid

description: The chemical reactions and pathways resulting in the formation of poly(hydroxyalkanoate) from fatty acid.


description: The chemical reactions and pathways resulting in the formation of poly(hydroxyvalerate).


description: The chemical reactions and pathways resulting in the formation of poly(hydroxyalkanoate).


A 2-acyl-sn-glycero-3-phosphocholine in which the acyl group is specified as (11R)-hydroxy-(5Z,8Z,12E,14Z)-icosatetraenoyl.


skin sensitivity to sun

description: The response of human skin to sun exposure.


phototoxic dermatitis

description: Dermatitis caused or precipitated by exposure to ultraviolet sunlight, or by mediating phototoxic or photoallergic material in response to ultraviolet sunlight.


photoallergic dermatitis

description: A delayed hypersensitivity involving the reaction between sunlight or other radiant energy source and a chemical substance to which the individual has been previously exposed and sensitized. It manifests as a papulovesicular, eczematous, or exudative dermatitis occurring chiefly on the light-exposed areas of the skin.


A chiral mycolic acid analogue comprising 3-hydroxypropanoic acid having a tetracosanyl group at position 2 and a further long-chain alkyl group containing cyclopropyl and methoxy functions attached at position 3.


skin pigmentation disorder

description: A pigmentation disease that involves the zone of skin.


acromelanosis

description: Acromelanosis is a congenital hyperpigmentation of the skin usually located on the acral areas of the fingers and toes. It is mostly observed in newborns or during the first years of life.


name: temperature-sensitive oculocutaneous albinism type 1

description: Type 1 temperature sensitive oculocutaneous albinism (OCA1-TS) is an extremely rare form of OCA1 characterized by the production of temperature sensitive tyrosinase proteins leading to dark hair on the legs, arms and chest (cooler body areas) and white hair on the scalp, axilla and pubic area (warmer body areas).


name: hyperpigmentation, progressive cribriform and zosteriform


description: Extrasystoles-short stature-hyperpigmentation-microcephaly syndrome is a rare, genetic, malformation syndrome with short stature characterized by microcephaly, borderline intellectual disability, hyperpigmentation of the skin, short stature, and ventricular extrasystoles. Cardiac syncope may also be associated. There have been no further descriptions in the literature since 1975.


Griscelli syndrome type 3

description: A Griscelli syndrome characterized by isolated silvery gray sheen of the hair and hypopigmentation of the skin that has material basis in mutation in the MLPH or MYO5A genes.


description: Hermansky-Pudlak syndrome without pulmonary fibrosis as a complication includes three relatively mild types (HPS-3, HPS-5 and HPS-6) of Hermansky-Pudlak syndrome (HPS), a multi-system disorder characterized by ocular or oculocutaneous albinism, bleeding diathesis and, in some cases, granulomatous colitis.


name: minimal pigment oculocutaneous albinism type 1

description: Type 1 minimal pigment oculocutaneous albinism (OCA1-MP) is an extremely rare form of OCA1 with minimal pigment present, characterized by blond hair, variable iris transillumination, visual acuity ranging from 20/80-20/200 and white skin, with or without skin nevi.


oculocutaneous albinism type 1

description: Type 1 oculocutaneous albinism (OCA1) describes a group of tyrosine related OCAs that includes OCA1A, OCA1B, type 1 minimal pigment oculocutaneous albinism (OCA1-MP) and type 1 temperature sensitive oculocutaneous albinism (OCA1-TS).


familial generalized lentiginosis

description: Familial generalized lentiginosis is a rare, inherited, skin hyperpigmentation disorder characterized by widespread lentigines without associated noncutaneous abnormalities. Patients present multiple brown to dark brown, non-elevated macula of 0.2 to 1 cm in diameter, spread over the entire body, sometimes including palms or soles, but never oral mucosa.


name: severe growth deficiency-strabismus-extensive dermal melanocytosis-intellectual disability syndrome


name: deaf blind hypopigmentation syndrome, Yemenite type

description: Yemenite deaf-blind hypopigmentation syndrome is an exceedingly rare genetic disorder characterized by cutaneous pigmentation anomalies, ocular disorders and hearing loss.


name: hypo- and hypermelanotic cutaneous macules-retarded growth-intellectual disability syndrome

description: Hypo- and hypermelanotic cutaneous macules-retarded growth-intellectual disability syndrome is a neurocutaneous syndrome characterized by congenital hypomelanotic and hypermelanotic cutaneous macules. It has been described in individuals spanning three generations of an Indian family. Some of the patients also had retarded growth and intellectual deficit.


Tietz syndrome

description: Tietz syndrome is a genetic hypopigmentation and deafness syndrome characterized by congenital profound bilateral sensorineural hearing loss and generalized albino-like hypopigmentation of skin, eyes and hair.


reticulate acropigmentation of Kitamura

description: A pigmentation disease characterized by lesions that initially arise as letiginous, hyperpigmented macules in a reticular pattern on the dorsal aspect of the hands and feet. Over time, lesions may spread proximally and may darken; palmoplantar pitting and dermatoglyphic disruption may also be present.


oculocutaneous albinism type 6

description: A form of oculocutaneous albinism characterized by light hair at birth that darkens with age, white skin, transparent irides, photophobia, nystagmus, foveal hypoplasia and reduced visual acuity.


Dowling-Degos disease 2

description: Any Dowling-Degos disease in which the cause of the disease is a mutation in the POFUT1 gene.


albinism-hearing loss syndrome

description: A syndromic genetic hearing loss is characterized by congenital nerve deafness and piebaldness with no ocular albinism. It has been described in one large pedigree. Transmission is X-linked with affected males presenting with profound sensorineural deafness and severe pigmentary abnormalities of the skin, and carrier females presenting with variable hearing impairment without any pigmentary changes. The causative gene has been mapped to Xq26.3-q27.1.


Hermansky-Pudlak syndrome 5

description: Any Hermansky-Pudlak syndrome in which the cause of the disease is a mutation in the HPS5 gene.


name: nail and teeth abnormalities-marginal palmoplantar keratoderma-oral hyperpigmentation syndrome

description: Nail and teeth abnormalities-marginal palmoplantar keratoderma-oral hyperpigmentation syndrome is a rare genetic ectodermal dysplasia syndrome characterized by short stature, nail dystrophy and/or nail loss, oral mucosa and/or tongue hyperpigmentation, dentition abnormalities (delayed teeth eruption, hypodontia, enamel hypoplasia), keratoderma on the margins of the palms and soles and focal hyperkeratosis on the dorsum of the hands and feet. Additionally, dysphagia with esophageal strictures, sensorineural deafness, bronchial asthma and severe iron-deficiency anemia have been observed.


Hermansky-Pudlak syndrome 7

description: Any Hermansky-Pudlak syndrome in which the cause of the disease is a mutation in the DTNBP1 gene.


Hermansky-Pudlak syndrome 9

description: Any Hermansky-Pudlak syndrome in which the cause of the disease is a mutation in the BLOC1S6 gene.


Dowling-Degos disease 4

description: Any Dowling-Degos disease in which the cause of the disease is a mutation in the POGLUT1 gene.


oculocutaneous albinism type 7

description: Oculocutaneous albinism type 7 (OCA7), formerly called OCA5, is a form of oculocutaneous albinism (OCA) characterized by skin and hair hypopigmentation, nystagmus and iris transillumination.


oculocutaneous albinism type 5

description: Oculocutaneous albinism type 5 (OCA5) is a type of oculocutaneous albinism found in one Pakistani family to date, characterized by white skin, golden hair, photophobia, nystagmus, foveal hypoplasia and impaired visual acuity, that affects males and females equally, and that has been mapped to a locus on chromosome 4q24 but whose gene has not yet been discovered.


name: dyschromatosis universalis hereditaria 1


Hermansky-Pudlak syndrome 8

description: Any Hermansky-Pudlak syndrome in which the cause of the disease is a mutation in the BLOC1S3 gene.


Griscelli syndrome

description: Griscelli syndrome (GS) is characterized by silvery gray sheen of the hair and hypopigmentation of the skin which can be associated to neurological impairment (type 1), immunodeficiency (type 2) or be isolated (type 3).


Griscelli syndrome type 1

description: A Griscelli syndrome characterized by silvery gray sheen of the hair, hypopigmentation of the skin and neurological impairment without immunodeficiency that has material basis in mutations in the MYO5A gene on chromosome 15q21.2.


Dowling-Degos disease

description: A pigmentation disease characterized by a reticulate pattern of abnormally dark skin coloring, particularly in the body's folds and creases.


description: Naegeli-Franceschetti-Jadassohn (NFJ) syndrome is a rare ectodermal dysplasia that affects the skin, sweat glands, nails, and teeth.


name: linear hypopigmentation and craniofacial asymmetry with acral, ocular and brain anomalies


Hermansky-Pudlak syndrome 10

description: Any Hermansky-Pudlak syndrome in which the cause of the disease is a mutation in the AP3D1 gene.


name: osteopathia striata-pigmentary dermopathy-white forelock syndrome

description: Osteopathia striata-pigmentary dermopathy-white forelock syndrome is characterized by the association of osteopathia striata (longitudinal striations through most of the long bones) with a macular, hyperpigmented dermopathy and a white forelock.


name: autosomal dominant oculocutaneous albinism

description: Autosomal dominant form of oculocutaneous albinism.


name: piebald trait-neurologic defects syndrome

description: Piebald trait-neurologic defects syndrome is a rare, genetic, pigmentation anomaly of the skin syndrome characterized by ventral as well as dorsal leukoderma of the trunk and a congenital white forelock, in association with cerebellar ataxia, impaired motor coordination, intellectual disability of variable severity and progressive, mild to profound, uni- or bilateral sensorineural hearing loss. There have been no further descriptions in the literature since 1971.


name: oculocerebral hypopigmentation syndrome, Cross type

description: Oculocerebral hypopigmentation syndrome, Cross type is a rare congenital syndrome characterized by cutaneous and ocular hypopigmentation, various ocular anomalies (e.g. corneal and lens opacity, spastic ectropium, and/or nystagmus), growth deficiency, intellectual deficit and other progressive neurologic anomalies such as spastic tetraplegia, hyperreflexia, and/or athetoid movements. The clinical picture varies among patients and may also include other anomalies such as urinary tract abnormalities, Dandy-Walker malformations, and/or bilateral inguinal hernia.


Hermansky-Pudlak syndrome 3

description: Any Hermansky-Pudlak syndrome in which the cause of the disease is a mutation in the HPS3 gene.


name: deafness, congenital, with total albinism


name: dyschromatosis universalis hereditaria 2


syndromic oculocutaneous albinism

description: A oculocutaneous albinism that is part of a larger syndrome.


name: hyperpigmentation with or without hypopigmentation, familial progressive


oculocutaneous albinism type 3

description: Type 3 oculocutaneous albinism (OCA3) is a form of oculocutaneous albinism (OCA) characterized by rufous or brown albinism and occurring mainly in the African population.


familial progressive hyperpigmentation

description: Familial progressive hyperpigmentation is a rare, genetic, skin pigmentation anomaly disorder characterized by irregular patches of hyperpigmented skin which present at birth or in early infancy and increase in size, number and confluence with age. Affected areas of the body include the face, neck, trunk and limbs, as well as the palms, soles, oral mucosa and conjuctiva. No hypogmentation macules are observed and no systemic diseases are associated.


oculocutaneous albinism type 1B

description: Oculocutaneous albinism type 1B (OCA1B) is a type of OCA1 characterized by skin and hair hypopigmentation, nystagmus, reduced iris and retinal pigment and misrouting of the optic nerves.


name: leukonychia totalis-acanthosis-nigricans-like lesions-abnormal hair syndrome

description: Leukonychia totalis-acanthosis-nigricans-like lesions-abnormal hair syndrome is a rare, syndromic nail anomaly disorder characterized by the association of leukonychia totalis with acanthosis-nigricans-like lesions (occurring in the neck, axillae and abdomen regions) and hair dysplasia, manifesting with dry, brittle hair which presents an irregular pattern of complete or incomplete twists and an irregular surface with londitudinal furrows on electronic microscopy.


oculocutaneous albinism type 1A

description: Oculocutaneous albinism type 1A (OCA1A) is the most severe form of OCA, where no melanin is produced, and is characterized by white hair and skin, blue, fully translucent irises, nystagmus and misrouting of the optic nerves.


name: dyschromatosis universalis hereditaria 3

description: Any dyschromatosis universalis hereditaria in which the cause of the disease is a mutation in the ABCB6 gene.


name: familial progressive hyper- and hypopigmentation

description: Familial progressive hyper- and hypopigmentation is a rare, genetic, skin pigmentation anomaly disorder characterized by progressive, diffuse, partly blotchy, hyperpigmented lesions that are intermixed with multiple café-au-lait spots, hypopigmented maculae and lentigines and are located on the face, neck, trunk and limbs, as well as, frequently, the palms, soles and oral mucosa. Dispigmentation pattern can range from well isolated café-au-lait/hypopigmented patches on a background of normal-appearing skin to confetti-like or mottled appearance.


description: Hyperkeratosis-hyperpigmentation syndrome describes a very rare hyperpigmentation of the skin characterized by tiny hyperpigmented spots mainly on skin exposed to sunlight, together with mild punctate palmoplantar papular hyperkeratosis as a major feature. There have been no further descriptions in the literature since 1993.


dyschromatosis symmetrica hereditaria

description: Acropigmentation of Dohi is a genodermatosis characterized by the presence of hyperpigmented and hypopigmented macules, principally located on the extremities and limbs.


oculocutaneous albinism type 2

description: Oculocutaneous albinism type 2 (OCA2) is a type of OCA and the most common form of OCA seen in the African population, characterized by variable hypopigmentation of the skin and hair, numerous characteristic ocular changes and misrouting of the optic nerves at the chiasm.


Ito hypomelanosis

description: Hypomelanosis of Ito (HI) is a multisystemic neurocutaneous condition with hypopigmented skin lesions along the Blaschko lines.


Dowling-Degos disease 1

description: Any Dowling-Degos disease in which the cause of the disease is a mutation in the KRT5 gene.


name: linear and whorled nevoid hypermelanosis

description: Linear and whorled nevoid hypermelanosis (LWNH) is a rare skin condition characterized by swirling streaks of hyperpigmented (darkened) skin. The pigmentation follows the lines of Blashko and is mainly located on the trunk and limbs. It is present at birth or appears in the first few weeks of life. It typically progresses for one to two years and then stabilizes. Hyperpigmentation is usually the only symptom but there are isolated reports of other symptoms, involving mostly the central nervous system, musculoskeletal system, and heart. While most cases of LWNH are sporadic, apparent genetic transmission rarely has been described. A few people with LWNH have been diagnosed with chromosomal mosaicism.


name: microcephaly 9, primary, autosomal recessive

description: Any autosomal recessive primary microcephaly in which the cause of the disease is a mutation in the CEP152 gene.


detection of parasitic plant

description: The series of events in which a stimulus from a parasitic plant is received and converted into a molecular signal.


detection of fungus

description: The series of events in which a stimulus from a fungus is received and converted into a molecular signal.


detection of symbiont

description: The series of events in which a stimulus from a symbiont (an organism living in close physical association with an organism of a different species) is received and converted into a molecular signal. The symbiont is defined as the smaller of the organisms involved in a symbiotic interaction.


detection of yeast

description: The series of events in which a stimulus from a yeast is received and converted into a molecular signal.


detection of other organism

description: The series of events in which a stimulus from another organism is received and converted into a molecular signal.


detection of symbiotic bacterium

description: The series of events in which a stimulus from a symbiotic bacterium, a bacterium living in close physical association with another organism, is received and converted into a molecular signal.


detection of bacterium

description: The series of events in which a stimulus from a bacterium is received and converted into a molecular signal.


detection of protozoan

description: The series of events in which a stimulus from a protozoan is received and converted into a molecular signal.


detection of oomycetes

description: The series of events in which a stimulus from an oomycetes is received and converted into a molecular signal.


An ammonium ion resulting from the protonation of the tertiary amino group of (-)-vincadifformine. The major species at pH 7.3.


polyketide biosynthetic process

description: The chemical reactions and pathways resulting in the formation of polyketides, any of a diverse group of natural products synthesized via linear poly-beta-ketones, which are themselves formed by repetitive head-to-tail addition of acetyl (or substituted acetyl) units indirectly derived from acetate (or a substituted acetate) by a mechanism similar to that for fatty acid biosynthesis but without the intermediate reductive steps.


fonsecin biosynthetic process

description: The chemical reactions and pathways resulting in the formation of fonsecin.


aspyridone A biosynthetic process

description: The chemical reactions and pathways resulting in the formation of aspyridone A.


mevastatin biosynthetic process

description: The chemical reactions and pathways resulting in the formation of mevastatin , also known as compactin or ML-236B, and which acts as a potent competitive inhibitor of HMG-CoA reductase.


erythromycin biosynthetic process

description: The chemical reactions and pathways resulting in the formation of erythromycin.


fumigermin biosynthetic process

description: The chemical reactions and pathways resulting in the formation of fumigermin, an alpha-pyrone secondary metabolite found in some species of fungi such as Aspergillus fumigatus.


oxytetracycline biosynthetic process

description: The chemical reactions and pathways resulting in the formation of oxytetracycline.


zearalenone biosynthetic process

description: The chemical reactions and pathways resulting in the formation of zearalenone, a mycotoxin produced by several Fusarium species, is most commonly found as a contaminant in stored grain and has chronic estrogenic effects on mammals.


tetracycline biosynthetic process

description: The chemical reactions and pathways resulting in the formation of tetracycline, (4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide, a broad-spectrum antibiotic produced by streptomyces bacteria that blocks binding of aminoacyl tRNA to the ribosomes of both Gram-positive and Gram-negative organisms (and those of organelles).


description: The chemical reactions and pathways resulting in the formation of dihydroxy naphthalene (DHN)-melanin.


averantin biosynthetic process

description: The chemical reactions and pathways resulting in the formation of averantin.


(M)-viriditoxin biosynthetic process

description: The chemical reactions and pathways resulting in the formation of (M)-viriditoxin, a fungal secondary metabolite with antibacterial activity.


granaticin biosynthetic process

description: The chemical reactions and pathways resulting in the formation of granaticin.


ilicicolin H biosynthetic process

description: The chemical reactions and pathways resulting in the formation of ilicicolin H, a 4-hydroxy-2-pyridone alkaloid that has potent and broad antifungal activities by inhibiting the mitochondrial respiration chain.


aspyridone B biosynthetic process

description: The chemical reactions and pathways resulting in the formation of aspyridone B.


epothilone biosynthetic process

description: The chemical reactions and pathways resulting in the formation of epothilone, a drug obtained from the myxobacteria Sporangium cellulosum that interferes with cell division. Some epothilones are being studied as treatments for cancer.


ansamycin biosynthetic process

description: The chemical reactions and pathways leading to the formation of ansamycins, any of a group of complex macrolactam compounds characterized by a cyclic structure in which an aliphatic ansa chain forms a bridge between two non-adjacent positions of a cyclic p-system; many exhibit antibacterial, antifungal or antitumor activity.


F-9775A biosynthetic process

description: The chemical reactions and pathways resulting in the formation of F-9775A.


patulin biosynthetic process

description: The chemical reactions and pathways resulting in the formation of patulin, an acetate-derived tetraketide mycotoxin produced by several fungal species that shows antimicrobial properties against several bacteria.


macrolide biosynthetic process

description: The chemical reactions and pathways leading to the formation of macrolides, any of a large group of polyketide compounds that contain a large lactone ring with few or no double bonds and no nitrogen atoms, linked glycosidically to one or more sugar groups. The macrolides include the carbomycins, the erythromycins, oleandomycin, oligomycins, and the spiramycins, and act as antibiotics, mainly against Gram-positive bacteria.


name: adenylate cyclase-activating adrenergic receptor signaling pathway involved in cardiac muscle relaxation

category: biolink:Pathway biolink:OntologyClass biolink:BiologicalProcess biolink:Occurrent biolink:BiologicalProcessOrActivity biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing biolink:PhysicalEssenceOrOccurrent

description: An adrenergic receptor signaling pathway that contributes to a reduction in cardiac muscle contraction. Beta-adrenergic receptor-induced cardiac relaxation is achieved by a GPCR-activated adenylate cyclase generating cAMP; cAMP then activates the cAMP-dependent protein kinase A (PKA), which phosphorylates the sarcoplasmic reticulum (SR) membrane protein PLB. In its non-phosphorylated state, PLB acts as an inhibitor of the ATPase Ca(2+) pump of the cardiac SR (SERCA2a); inhibition of the pump is relieved upon phosphorylation. The pump removes Ca(2+) from the cytoplasm, thereby preventing cytosolic Ca(2+)-dependent activation of contractile proteins, leading to enhanced muscle relaxation.